Melanotan Side Effects Found in Small Studies and Reports
Nausea and a warm face were the most common effects
Arizona researchers first made MT-II to help skin grow darker. Their 1996 and 1998 studies also found nausea, a warm red face, tiredness, yawning, and stretching [3][5][6].
One study raised the amount over several days. The other used one amount based on each man's weight.
A 2017 rat study helps explain the yawning and nausea. MT-II stirred brain cells that release oxytocin, a hormone involved in those reflexes [26].
In the small human studies, nausea was often brief and worse at higher amounts. That doesn't tell you what an unknown product or larger amount may do to you.
A 2021 paper examined 623 posts from 205 people using MT-II [23]. Those writers called it research use, but they weren't members of a controlled study. No trial checked what caused each complaint.
Nausea and a warm red face appeared most often in those posts. Without a clinic checking the product and amount, you can't know the cause.
Two men had serious kidney harm after using MT-II
Two published reports describe grave kidney trouble after MT-II use. Each concerns one man, so neither gives your risk.
Case 1, 2020. A 45-year-old man used 27 milligrams over 6 months. A clot stopped blood flow to about 50% of his right kidney [11].
The paper called his swelling blood test high at 152 milligrams per liter. It called creatinine, a kidney-check waste product, high at 102 micromoles per liter, a unit for tiny amounts.
His blood pressure was high at 165/95 millimeters of mercury, the usual pressure unit. Blood also appeared in his urine.
A later test put kidney filtering at 81 milliliters a minute, which was mildly low. The authors couldn't prove MT-II caused the clot.
Case 2, 2012. A 39-year-old man gave himself 6 milligrams in one shot. That was about 6 times the early study's starting amount.
After 12 hours, his muscle-damage blood test reached 17,773 units per liter, far above normal. His kidney blood work then showed a sudden injury.
He needed intensive hospital care for 3 days [12]. You can't assume a smaller amount removes the risk.
Both men used much more than the early studies tested. The reports raise concern for you, but they don't prove the cause.
Two reports describe moles that darkened or changed
Published reports describe new or fast-changing moles after melanotan use. Ireland's and Australia's drug agencies also warn about mole changes.
Case 1, 2012. A 25-year-old man developed many new moles, while old ones changed fast. Some cells had severe abnormal changes, but the report didn't call them cancer [13].
Case 2, 2012. A 16-year-old with a family illness tied to many moles and skin cancer used MT-II and tanning beds. She developed dark moles, including a growing one in her groin, though some color faded after she stopped [14].
The skin receptor tells pigment-making cells to work. Reaching that receptor may also stir pigment cells inside a mole.
The younger person had a known family risk, but the man had no reported family risk. You can't limit the concern to families already known to be at risk.
Studies that keep reaching this skin receptor include regular skin checks. A check looks for new moles or quick changes in old ones.
MT-I has a much longer safety record than MT-II
MT-I has formal drug trials and years of follow-up in patients. One 8-year study followed 115 people through 1,023 implants, with nausea mostly mild [16].
MT-II doesn't have that depth of safety study for you to read. Human work from the 1990s–2000s included only 3–20 people and used amounts based on body weight.
Nausea was the main unwanted effect in those small studies. Reports on single patients describe grave harm, but no rate is known.
The US drug agency says MT-II isn't approved and can't lawfully be sold for human use. Australia's drug agency also says it isn't approved for sale.
Irish and UK drug agencies have active warnings about MT-II. They warn about an unlicensed drug, not an approved prescription medicine.
The missing safety review is the point that matters for your health. No government health agency has approved MT-II as a medicine.
No government health agency has approved MT-II
MT-I is approved in the EU and US for EPP, a painful illness caused by light. Patients receive it by prescription with medical follow-up.
MT-II isn't approved in the US, EU, Australia, Ireland, or the UK. Its human safety record comes from studies of only 3–20 people and reports about single patients.
Early studies used weight-based amounts while a clinic watched each man. The grave reports involved much higher total amounts without that care.
This page tells you what the studies and reports found. No page can decide whether MT-II is safe, legal, or right for your health.
Clinical access is a separate question
Evaluation does not change the evidence
Promise Peptides clinicians may prescribe Melanotan II after evaluating an individual case; mypromise.com presents that access through a licensed, prescription-only care pathway, not as evidence that the compound is FDA-approved or suitable for self-directed use.
Human Melanotan II studies didn't measure testosterone
No controlled human study has tested whether MT-II raises or lowers testosterone. A firm claim in either direction isn't backed by a trial.
One rat study measured the brain's orders to glands that make sex and growth hormones. MT-II changed eating and fat but didn't change those orders [22].
MT-II can cause erections through a switch in the brain. That route doesn't need a rise in testosterone.
Human MT-II studies didn't measure testosterone as a main or extra result. With no measurement, you don't have a human answer.
Keep erections and testosterone as two different body processes. An erection doesn't prove that testosterone rose or fell.